Compare MCD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCD | GILD |
|---|---|---|
| Founded | 1940 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3B | 187.5B |
| IPO Year | 1995 | 2000 |
| Metric | MCD | GILD |
|---|---|---|
| Price | $331.21 | $147.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 18 |
| Target Price | ★ $340.12 | $143.50 |
| AVG Volume (30 Days) | 3.3M | ★ 6.6M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.22% | 2.19% |
| EPS Growth | 4.92 | ★ 1684.21 |
| EPS | ★ 11.95 | 6.78 |
| Revenue | ★ $26,885,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $8.35 | $4.68 |
| Revenue Next Year | $5.73 | $5.81 |
| P/E Ratio | $28.06 | ★ $22.14 |
| Revenue Growth | 3.72 | ★ 9.98 |
| 52 Week Low | $283.47 | $95.30 |
| 52 Week High | $341.75 | $157.29 |
| Indicator | MCD | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 54.35 |
| Support Level | $295.03 | $108.90 |
| Resistance Level | $335.67 | $157.29 |
| Average True Range (ATR) | 5.94 | 4.15 |
| MACD | -0.03 | -1.31 |
| Stochastic Oscillator | 51.20 | 34.29 |
McDonald's is the world's largest restaurant brand, with nearly $131 billion in systemwide sales across more than 44,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 61%), with the remainder stemming from company-operated restaurants across three segments: the United States (41% of systemwide sales), international operated markets (34%), and international developmental/licensed markets (25%).
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).